AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7679737
Drug: Hydromorphone (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.75, 1.5 and 3 mg)
Trial: 7679737
Drug: Pentazocine (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (15, 30 and 60 mg)
Trial: 30833436
Drug: Irinotecan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (150 mg/m2) administered intravenously over 90 min on day 1, and S-1 (80 mg/m2) given orally in two divided doses from days 1 to 14 of a 21 day cycle.
Trial: 21047625
Drug: Non-search paradigm
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-search paradigm testing with an agent demonstrating a rattling object
Trial: 17984395
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs) including olanzapine, quetiapine fumarate, risperidone
Trial: 17984395
Drug: Placebo (representing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (representing a 'watchful waiting' treatment strategy)
Trial: 14638565
Drug: Weekly patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly patient self-management with phenprocoumon
Trial: 14638565
Drug: Weekly management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly management at an anticoagulation clinic with phenprocoumon
Trial: 14638565
Drug: Weekly management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly management with acenocoumarol
Trial: 10823572
Drug: Mandatory vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory vaccination program for HCWs (intramuscular half dose from 1990 to 1995, intradermal from 1983 to 1989)
Trial: 1626674
Drug: Lignocaine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine at a dose of 0.2 mg.kg‐1
Trial: 6093979
Drug: High-dose CAV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CAV (HD-CAV) - cyclophosphamide 1200 mg/m2, doxorubicin 70 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21
Trial: 6093979
Drug: Conventional-dose CAV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CAV + VP-16 (CAV-VP) - cyclophosphamide 1000 mg/m2, doxorubicin 40 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21 with VP-16 100 mg/m2 on days 1-3 and 21-23
Trial: 3742319
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg PO the night prior to surgery and 300 mg IV 30 minutes prior to anaesthesia induction (Part 1)
Trial: 29550085
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor
Trial: 29550085
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT)
Trial: 29550085
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin plus DAPT
Trial: 24171782
Drug: Individualized acupuncture
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized acupuncture point prescriptions, 20 sessions over four weeks.
Trial: 24171782
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group, no treatment for 24 weeks, followed by 20 acupuncture treatments for free.
Trial: 18312057
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day for 10 weeks
Trial: 17025273
Drug: Darbepoetin alfa,
RxNorm normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa, subcutaneous doses of 0.5 microg/kg every week to 15 microg/kg every 3 weeks
Trial: 17025273
Drug: Darbepoetin alfa,
RxNorm normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa, intravenous and subcutaneous doses of 2.25 microg/kg every week and 6.75 microg/kg every 3 weeks
Trial: 17025273
Drug: Darbepoetin alfa,
RxNorm normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa, subcutaneous doses
Trial: 10945387
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus infusions of 1,000 IU AT III every 4 h for 4 days (total dose: 30,000 IU AT III)
Trial: 10945387
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 250 IU AT III/h for 4 days (total dose: 30,000 IU AT III)
Trial: 10945387
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (Intermittent bolus and Continuous infusion)
Trial: 1532964
Drug: Lithium succinate
RxNorm normalized name: lithium succinate
DrugBank: Lithium succinate (DB14508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium succinate ointment (8%)
Trial: 31000320
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement with HMB 1200mg, l‐glutamine 7000mg, and l‐arginine 7000mg administered once or twice per day for 14‐28 days preoperatively.
Trial: 1708969
Drug: Prednisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (2 mg/kg/24 h in three divided doses)
Trial: 25475116
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nitisinone
Trial: 25475116
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nitisinone
Trial: 25475116
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nitisinone
Trial: 25475116
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg nitisinone
Trial: 11591618
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg oral dose)
Trial: 11339516
Drug: meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 15 mg
Trial: 8630640
Drug: piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam 20 mg
Trial: 7849250
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 100 mg/day
Trial: 7849250
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg thrice daily added to thiazide and placebo regimens
Trial: 16547387
Drug: Insulin-dependent diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetes mellitus group
Trial: 12381983
Drug: Traditional chiropractic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional chiropractic treatment (nonintervention group)
Trial: 8536868
Drug: New treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatments for inflammatory bowel disease (specific interventions not detailed in the abstract)
Trial: 2180981
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human GH treatment
Trial: 543202
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day Perhexilinmaleat
Trial: 543202
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day Perhexilinmaleat
Trial: 25633470
Drug: Modifying Phonation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifying Phonation Intervals (MPI) treatment
Trial: 25633470
Drug: Prolonged speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged speech treatment
Trial: 15951310
Drug: 4% dimeticone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% dimeticone lotion
Trial: 15188980
Drug: Expressed breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressed breast milk (EBM) 5 ml
Trial: 15188980
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water (DW) 5 ml (placebo)
Trial: 11480129
Drug: Pioglitazone (Actos),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (Actos), specific dosage and duration not mentioned
Trial: 2694853
Drug: Better chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Better chemotherapy regimens and bone marrow transplantation
Trial: 30388950
Drug: Guided mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided mindfulness practice (daily using an audio CD)
Trial: 28637246
Drug: Psilocybin (0.215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (0.215 mg/kg p.o.)
Trial: 15836710
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg once daily
Trial: 19741494
Drug: Ephedrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (10 mg)
Trial: 16500392
Drug: Scheduled maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled maintenance treatment with infliximab (3 doses)
Trial: 16500392
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment with infliximab (single dose)
Trial: 16500392
Drug: Scheduled maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled maintenance treatment with infliximab
Trial: 16500392
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment with infliximab
Trial: 16500392
Drug: Scheduled infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Scheduled infliximab maintenance therapy
Trial: 11716203
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of prednisolone p.o. for 1 week
Trial: 11716203
Drug: 1600 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 microg of inhaled budesonide daily for 1 week
Trial: 11716203
Drug: 1600 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 microg of inhaled budesonide daily for 3 weeks (after initial treatment)
Trial: 31859197
Drug: Intravenous dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexketoprofen (systemic therapy)
Trial: 30854836
Drug: Guided implant
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided implant surgery
Trial: 23332456
Drug: Osmotic-release oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-release oral system methylphenidate (OROS-MPH) 18, 36, or 54 mg/day
Trial: 21654267
Drug: Febuxostat 20
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 20 mg/d for 7 days
Trial: 15569270
Drug: Inflaban (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflaban (100 mg) suppository
Trial: 15569270
Drug: Voltaren (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voltaren (100 mg) suppository
Trial: 8295812
Drug: Clarithromycin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (7.5 mg/kg twice daily for 7 to 10 days)
Trial: 8295812
Drug: Amoxicillin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (20 mg/kg twice daily for 7 to 10 days)
Trial: 29438162
Drug: Serum insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum insulin (highest vs. lowest quartile)
Trial: 29438162
Drug: Serum glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum glucose and insulin
Trial: 26117922
Drug: Cardioxipin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioxipin (10 mg/kg daily i/v droplet infusion)
Trial: 26117922
Drug: Cytoflavin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (10 ml in 200 ml 0.9% sodium chloride solution daily i/v droplet infusion for 10 days)
Trial: 26117922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with cytoflavin and cardioxipin)
Trial: 14672354
Drug: Calcitonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin treatment (not specified dosage or duration)
Trial: 14672354
Drug: No calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No calcitonin treatment (control group)
Trial: 10852316
Drug: Perioperative NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative NSAIDs (medium-to-high-dose regimens)
Trial: 6329769
Drug: Oxyphenonium bromide
RxNorm normalized name: oxyphenonium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxyphenonium bromide 3 X 10 mg
Trial: 6329769
Drug: Terbutaline 3
RxNorm normalized name: terbutaline 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 3 X 5 mg
Trial: 6329769
Drug: Theophylline 2
RxNorm normalized name: theophylline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 2 X 300 mg
Trial: 31545671
Drug: 3% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% prilocaine with 0.03 IU/mL felypressin (P + FP)
Trial: 31545671
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:80,000 adrenaline (L + AD)
Trial: 29723393
Drug: Bortezomib added
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib added to rituximab, high‐dose methotrexate, and high‐dose cytarabine (BzR‐MA)
Trial: 26213242
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to Daily Occupational Performance (CO‐OP) intervention for 10 weeks
Trial: 24658945
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection (group H + A)
Trial: 24658945
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound treatment (group H)
Trial: 23100167
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet of mitiglinide and metformin (10 mg/500 mg)
Trial: 23100167
Drug: Individual formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual formulations of mitiglinide and metformin
Trial: 23100167
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FDC and individual formulations)
Trial: 18846346
Drug: 0.4% carbomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% carbomer gel
Trial: 8839230
Drug: ITF 296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 296 (10, 20, 40, 80 micrograms/kg) by 1-min i.v. injection
Trial: 2202551
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (3.0 g/day)
Trial: 2202551
Drug: Enteric-coated acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated acetylsalicylic acid (3.0 g/day)
Trial: 28338566
Drug: Midazolam (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.06 mg/kg)
Trial: 21904779
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg)
Trial: 25834684
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral examination format (n=17)
Trial: 24166470
Drug: Elective stenosis
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective stenosis repair (treatment group)
Trial: 21480257
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment and adjuvant radiotherapy
Trial: 15579215
Drug: Nicotine administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine administered by patch
Trial: 11684377
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CA) 10 mg/day
Trial: 11836042
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (MP) 200 mg/day
Trial: 9888411
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (7 g three times per day)
Trial: 9888411
Drug: Placebo (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7 g glycine three times per day)
Trial: 21585330
Drug: 10mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg of intravenous metoclopramide
Trial: 21585330
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous paracetamol
Trial: 11098022
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) with frozen-thawed epididymal spermatozoa
Trial: 31475367
Drug: Sildenafil (0.42-2.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (0.42-2.09 mg/kg enterally) in cohort 1
Trial: 31475367
Drug: Sildenafil (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (0.125 or 0.25 mg/kg IV) in cohort 2
Trial: 31475367
Drug: IV doses
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV doses of 0.125, 0.5 and 1 mg/kg every 8 hours (in absence of fluconazole)
Trial: 24708672
Drug: Practice team-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice team-supported self-managed exposure programme with cognitive behaviour therapy-oriented psychoeducation and instructions in four manual-based appointments, plus ten protocol-based telephone contacts for symptom monitoring.
Trial: 20511029
Drug: Sequential Compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Compression Device (SCD)
Trial: 10227007
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEE) for 21 days
Trial: 10227007
Drug: Oral CEE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CEE for 21 days followed by 5 mg/day of medrogestone for 7 days
Trial: 1650303
Drug: Experimental dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dentifrice formulations (specific formulations not detailed)
Trial: 29440218
Drug: Ramipril (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (active treatment group)
Trial: 27558421
Drug: Oral Preexposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Preexposure Prophylaxis (PrEP) with tenofovir
Trial: 11772951
Drug: 3.8-4.0 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.8-4.0 g plant stanol esters daily for 8 weeks
Trial: 10680989
Drug: DT‐IPV (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT‐IPV (50 Lf, 12.5 Lf, 40, 8, 32 DU) at 5, 6 and 15 months of age plus whole‐cell pertussis vaccine (> or = 4 IU) at 5 and 9 weeks and at 10 months of age, n = 84
Trial: 2257857
Drug: Cicletanine 100
RxNorm normalized name: cicletanine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 100 mg
Trial: 2344503
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg
Trial: 7428646
Drug: Fendiline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendiline (3 X 50 mg)
Trial: 7428646
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) (2 X 20 mg plus 1 placebo tablet)
Trial: 28254636
Drug: MIRT (multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRT (multidisciplinary intensive rehabilitation treatment)